ENDPOINTS

Bristol Myers prunes pipeline amid new round of cost cuts

Bristol Myers Squibb is ending work on a handful of assets, including an immunol...

Acelyrin and Alumis to merge in deal combining cash, as...

After running into clinical hurdles with its “diamond in the rough” strategy, Lo...

Sionna inks $191M IPO for cystic fibrosis pipeline as A...

Cystic fibrosis biotech Sionna Therapeutics will raise $191 million in its upsiz...

Novo Nordisk takes aim at Roche in hemophilia A, but is...

Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in ...

Longtime Sandoz exec announces retirement; Lilly appoin...

→ Francisco Ballester is retiring as president, region international at Sandoz o...

Bain buys Mitsubishi Tanabe Pharma in $3.3B bet on Japan

The Mitsubishi Chemical Group is selling its centuries-old pharmaceutical busine...

Bioluminescence Ventures to shut down 15 months after l...

The life science investment firm Bioluminescence Ventures will close its doors l...

Doctors complete fourth xenotransplant of gene-edited p...

A 66-year-old man whose kidneys were failing is now the fourth person who has re...

Major FDA staff cuts would slow drug reviews, experts say

The Trump administration's reported plans to potentially lay off thousands of FD...

Post-Hoc: China tensions both help and hurt Illumina

In the souring US-China relationship, there are winners and losers. DNA sequenci...

Sanofi, AstraZeneca back Teva's call to rehear case on ...

Sanofi, AstraZeneca and two leading trade groups want clarity around an appellat...

Senators ask FDA to dig into 'misleading' Super Bowl ad...

Sens. Dick Durbin (D-IL) and Roger Marshall (R-KS) are calling on the FDA to tak...

Q4 earnings updates; Biogen details revised research st...

Welcome back to Endpoints Weekly! Our team tracked fourth-quarter earnings repor...

AbbVie wins FDA approval for new antibiotic

The FDA approved AbbVie and Pfizer's drug Emblaveo in combination with an older ...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.